• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (19)
    • Sub-clinical dose of bone morphogenetic protein-2 does not precipitate rampant, sustained inflammatory response in bone wound healing.
    • Single Person
    • Frain, Bryan
    • Dhakal , Rashmi
    • Differential efficacy of human mesenchymal stem cells based on source of origin.
    • See All 19 Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

Differential efficacy of human mesenchymal stem cells based on source of origin.

Differential efficacy of human mesenchymal stem cells based on source of origin. J Immunol. 2014 Nov 01; 193(9):4381-90.

View in: PubMed

subject areas
  • Adult
  • Animals
  • B-Lymphocytes
  • Bone Marrow
  • Cell Differentiation
  • Cytokines
  • Disease Models, Animal
  • Female
  • Gene Expression
  • Humans
  • Immunophenotyping
  • Inflammation Mediators
  • Kidney
  • Lupus Erythematosus, Systemic
  • Male
  • Mesenchymal Stem Cell Transplantation
  • Mice
  • Mice, Inbred MRL lpr
  • Phenotype
  • Tissue Donors
  • T-Lymphocytes
  • Treatment Outcome

authors with profiles
  • Gary S. Gilkeson